Clinical trials: Epithelial Tumor, Malignant
Kidney Tumors
Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy…
- Trial name
- NCT01401777
- Where
- United States
- Sponsor
- Philips Healthcare
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options…
- Conditions
- Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
- Trial name
- BOSS (NCT06055881)
- Testing
- Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer.
- Trial name
- NCT00819728
- Testing
- Docetaxel, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sanofi
Cervical Cancer, Anal Cancer
Detecting HPV DNA in Anal and Cervical Cancers
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer.
- Conditions
- Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma
- Trial name
- NCT04857528
- Testing
- Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Adrenocortical Carcinoma
Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Despite complete resection of early-stage disease recurrence rates in ACC are very high (60%.70%).
- Trial name
- ACACIA (NCT03723941)
- Testing
- Cisplatin plus Etoposide, Observation or Mitotane
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03698994
- Testing
- Pharmacokinetic Study, Ulixertinib
- Where
- 107 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases, Non-small Cell Lung Cancer
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis.
- Trial name
- NCT06020066
- Testing
- EGFR-TK Inhibitor, Stereotactic radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II-IV ovarian epithelial, fallopian tube, or…
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT00989651
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 23 sites in United States
- Volunteers
- 431 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Neuroendocrine Tumors, Carcinoma;Endocrine
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.
- Trial name
- NET (NCT05168631)
- Where
- 8 sites in Argentina, Brazil and 2 more
- Volunteers
- 88 people
- Sponsor
- Latin American Cooperative Oncology Group
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05068102
- Testing
- BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma of Larynx
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with…
- Trial name
- SMART-KEY (NCT04943445)
- Testing
- carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles, Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles., Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
- Where
- 9 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Latin American Cooperative Oncology Group
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, [18F]FluorThanatrace ([18F]FTT).
- Trial name
- NCT07114939
- Testing
- [18F]FluorThanatrace
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
- Trial name
- NCT05681039
- Testing
- Tiragolumab, Atezolizumab, Standard of Care
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal…
- Trial name
- WISE (NCT00090857)
- Testing
- Letrozole
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00066612
- Testing
- irinotecan hydrochloride
- Volunteers
- 45 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired.
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT07104630
- Testing
- Pulmonary Rehabilitation (PR), No intervention: Usual care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Case Comprehensive Cancer Center
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.